Recent Updates
Recently added Catalysts
ARCT Positive Sentiment

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

Friday, September 18, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Arcturus Therapeutics Holdings Inc. is set to present Phase 2 clinical data for its ARCT-810 program targeting Ornithine transcarbamylase deficiency. The virtual presentation is scheduled for September 23, 2026, and will also cover updates on the company's mRNA liver therapeutics platform. This event highlights the company's commitment to developing treatments for rare diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Arcturus is advancing its Phase 2 clinical program for OTC deficiency.
  • The company is focused on innovative mRNA liver therapeutics.
  • The upcoming presentation will provide valuable insights into their research.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
5%
average across 5 past catalysts
Cash runway
~28 mo
Minimal dilution risk
Lead asset
ARCT-2303
Phase 3 · COVID-19

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that it will host a virtual presentation on Wednesday, September 23, 2026, at 4:30 p.m. ET. The presentation will provide an overview of the ARCT-810 Phase 2 clinical program for Ornithine transcarbamylase (OTC) deficiency and Arcturus’ mRNA liver therapeutics pl

Frequently Asked Questions

What is the focus of Arcturus Therapeutics?

Arcturus Therapeutics focuses on developing messenger RNA medicines for liver and respiratory rare diseases.

When will the presentation on OTC deficiency take place?

The presentation is scheduled for September 23, 2026, at 4:30 p.m. ET.

What will be discussed in the upcoming presentation?

The presentation will cover the Phase 2 clinical program for OTC deficiency and updates on mRNA liver therapeutics.

ShareAdd on Google
Tags: ARCT Viatris Investor Conferences Healthcare Arcturus Therapeutics OTC deficiency Phase 2 clinical trial mRNA therapeutics liver disease
Last updated: Sep 18, 2026

Biotech snapshot

Cash runway
$191M liquidity · $7M/mo burn
~28 mo
Minimal dilution risk
Lead asset
ARCT-2303Phase 3
COVID-19 →

Catalyst track record

+36%
best trade around ARCT's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for ARCT.

See every catalyst's timing & PoA →